(Q34059396)

30 July 2017

title

Desirudin: a review of its use in the management of thrombotic disorders (English)

1 reference

30 July 2017

A J Matheson

1

1 reference

30 July 2017

K L Goa

series ordinal

2

1 reference

30 July 2017

publication date

1 September 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

60

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

679-700

1 reference

Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin

30 July 2017

cites work

1 reference

12 December 2020

Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.

1 reference

12 December 2020

Hirudins: antithrombin anticoagulants

1 reference

12 December 2020

Newer antithrombin agents in acute coronary syndromes

1 reference

12 December 2020

Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).

1 reference

12 December 2020

Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous administration

1 reference

12 December 2020

Direct thrombin inhibitors: current status and future prospects

1 reference

12 December 2020

An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent.

1 reference

12 December 2020

Future prospects of prophylaxis for deep vein thrombosis

1 reference

12 December 2020

Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators

1 reference

12 December 2020

Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial

1 reference

12 December 2020

Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial

1 reference

12 December 2020

Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin.

1 reference

12 December 2020

Hirudin versus heparin and low-molecular-weight heparin: and the winner is...

1 reference

12 December 2020

Biology of recombinant hirudin (CGP 39393): a new prospect in the treatment of thrombosis

1 reference

12 December 2020

Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group

1 reference

12 December 2020

Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators

1 reference

12 December 2020

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

1 reference

12 December 2020

Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: Experience from GUSTO-IIb

1 reference

12 December 2020

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

12 December 2020

A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial

1 reference

12 December 2020

Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.

1 reference

12 December 2020

Economic evaluation of desirudin vs heparin in deep vein thrombosis prevention after hip replacement surgery

1 reference

12 December 2020

Past, present and future of hirudin

1 reference

12 December 2020

Antithrombotic agents and thromboembolic disease

1 reference

12 December 2020

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

1 reference

12 December 2020

Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement

1 reference

12 December 2020

A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators

1 reference

12 December 2020

Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers

1 reference

12 December 2020

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

1 reference

12 December 2020

Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin

1 reference

12 December 2020

Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coron

1 reference

12 December 2020

Recombinant hirudins: an overview of recent developments

1 reference

12 December 2020

10.2165/00003495-200060030-00012

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1025325464

0 references

1 reference